Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC

INTRODUCTION: Durvalumab consolidation therapy is the standard of care after concurrent chemoradiotherapy (CRT) for stage III NSCLC. Immune-related pneumonitis during durvalumab treatment is potentially fatal; however, information is lacking regarding the impact of pneumonitis on patient survival. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinehara, Yuhei, Shiroyama, Takayuki, Tamiya, Akihiro, Tamiya, Motohiro, Minami, Seigo, Kanazu, Masaki, Morimura, Osamu, Niki, Toshie, Tetsumoto, Satoshi, Taniguchi, Yoshihiko, Kuge, Tomoki, Nishino, Kazumi, Nagatomo, Izumi, Kumanogoh, Atsushi, Tachibana, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679942/
https://www.ncbi.nlm.nih.gov/pubmed/38029024
http://dx.doi.org/10.1016/j.jtocrr.2023.100586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679942/
https://www.ncbi.nlm.nih.gov/pubmed/38029024
http://dx.doi.org/10.1016/j.jtocrr.2023.100586

Ejemplares similares